apl-2 and c3 inhibition
Published 5 years ago • 1K plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
54:24
controversy: dual vs triple antithrombotic therapy in af patients undergoing pci. what’s best?
-
23:15
workshop 3 anticoagulation in a complex patient, e.g. cad±pci af
-
4:42
activated phosphoinositide 3-kinase delta syndrome, apds (nord)
-
53:33
case-based session: management of antithrombotic therapy in complex pci scenarios
-
4:35
lawrence garcia, c3 2019 – paclitaxel and superficial femoral artery treatment
-
7:58
acetylcholinesterases and acetylcholinesterase inhibitors part 3
-
19:10
acs / antithrombotics - s. wassmann
-
0:27
simulations of thrombotic adhesion to arteriosclerotic lesions
-
8:27
pembrolizumab, secukinumab, ustekinumab biosimilar, vonoprazan, abatacept, exa-cel
-
20:59
the blessing and curse of direct oral anticoagulants in the bleeding patient
-
20:34
which is the best new oral anticoagulant ?
-
18:58
acb intrinsic apoptosis and p53
-
1:28
isico pill - "scapola prominente" presentato da claudio sedicino, ft
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
19:51
anticoagulation for crrt alexander zarbock 2023
-
4:24
lipid-lowering medications
-
2:37
esc 2019: circulating dipeptidyl peptidase-3 - prof alexandre mebazaa
-
4:30
thrombolisis contraindications
-
0:47
dr. arteaga on pi3k pathway inhibitors
-
5:42
truncus arteriosus
-
12:04
bacterial persistance part 3
-
3:59
role of pi3k inhibitors in treatment of b-cell malignancies